Summary
Enprofylline 1 mg/kg, a new potent antiasthmatic xanthine derivative, which is mainly eliminated by renal excretion, was given intravenously to 6 normal subjects with and without oral pretreatment with 1 g probenecid. The latter caused a drop in the average total body clearance of enprofylline from 21 to 9.8 l/h, and in the average renal clearance from 17 to 8.0 l/h. The average half-life increased from 1.8 to 3.0 h. The volumes of distribution, Vz and Vss, both fell by about 25%, indicating that probenecid had restricted the distribution of enprofylline in the body. The plasma protein binding of enprofylline was not altered by probenecid. The results confirm the opinion that active tubular secretion accounts for a large proportion of the total elimination of enprofylline.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arvidsson A, Borgå O, Kager L, Pieper R (1981) Renal elimination of cefoxitin and effect of probenecid after single and repeated doses. J Antimicrob Chemother 7: 423–430
Borgå O, Andersson K-E, Edholm L-E, Fagerström P-O, Lunell E, Persson CGA (1984) Enprofylline kinetics in healthy subjects after single doses. Clin Pharmacol Ther 34: 799–804
Gibaldi M, Davidson D, Plaut ME, Schwartz MA (1970) Modification of penicillin distribution and elimination by probenecid. Int J Clin Pharm Ther Tox 3: 182–189
Levy G, Koysooko R (1976) Renal clearance of theophylline in man. J Clin Pharmacol 16: 329–332
Lunell E, Borgå O, Larsson R (1984) Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose. Eur J Clin Pharmacol 26: 87–93
Lunell E, Svedmyr N, Andersson K-E Persson CGA (1982) Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease. Eur J Clin Pharmacol 22: 339–402
May DC, Jarboe CH (1983) Effects of probenecid on dyphylline elimination. Clin Pharmacol Ther 33: 822–825
Persson CGA, Erjefält I, Edholm L-E, Karlsson J-A, Lamm C-J (1982) Tracheal relaxant and cardiostimulant actions of xanthines can be differentiated from diuretic and CNS-stimulant effects. Role of adenosine antagonism? Life Sci 31: 2673–2681
Persson CGA, Erjefält I, Karlsson J-A (1981) Adenosine antagonism, a less desirable characteristic of xanthine asthma drugs? Acta Pharmacol Toxicol 49: 317–320
Persson CGA, Kjellin G (1981) Enprofylline, a principally new antiasthmatic xanthine. Acta Pharmacol Toxicol 49: 313–316
Smith DE, Gambertoglio JG, Vincenti F, Benet LZ (1981) Furosemide kinetics and dynamics after kidney transplant. Clin Pharmacol Ther 30: 105–113
Tegnér K, Annerfeldt JE, Svensson I (1985) The pharmacokinetics of enprofylline in animals. In: Andersson K-E, Persson CGA (eds) Anti-asthma xanthines and adenosine. Excerpta Medica
Tegnér K, Borgå O, Svensson I (1983) Protein binding of enprofylline. Eur J Clin Pharmacol 25: 703–708
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Borgå, O., Larsson, R. & Lunell, E. Effects of probenecid on enprofylline kinetics in man. Eur J Clin Pharmacol 30, 221–223 (1986). https://doi.org/10.1007/BF00614308
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00614308